leisure time -WSS

leisure time

author：hotspot 2025-09-06 05:03:10 - browse：53

An import ban of certain Apple Watches officially goes into effect on Tuesday. Justin Sullivan/Getty Images

An import ban of certain Apple Watches officially goes into effect on Tuesday, after the U.S. International Trade Commission deemed the blood oxygen measurement feature too similar to products patented by pulse oximetry company Masimo. It’s the first time Apple has ever faced such a ban.

President Biden had the chance to veto the ban until Christmas day, but he didn’t, as a statement from his trade representative made clear Tuesday morning. Now, Apple has to decide how much it values this feature, and if it’s willing to take a hit on its journey to establish the Apple Watch as a necessary public health tool.

“We strongly disagree with the USITC decision and resulting exclusion order, and are taking all measures to return Apple Watch Series 9 and Apple Watch Ultra 2 to customers in the U.S. as soon as possible,” Apple spokesperson Nikki Rothberg wrote in an email to STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Medicare Advantage insurers face 0.2% cut to 2025 payments

hotspot

WSS

Medicare Advantage insurers face 0.2% cut to 2025 payments

In same hospitals, Black patients receive fewer opioids than white patients

FDA panel issues narrow recommendation for Covid vaccine booster doses

Why you shouldn’t ask, “What country has the best health care?”

Drastic changes should bring profitability, startup health insurers say

Methadone doses haven’t kept up in the age of fentanyl

focus

leisure time

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Bernie Sanders is gearing up to subpoena pharma CEOs

Medicare details structure of new drug price negotiation program

Biogen walks away from Aduhelm, years after polarizing approval

In age of alternative facts, a scholarly course on calling out crap

Drastic changes should bring profitability, startup health insurers say

Duchenne breakthrough therapy leaves behind pioneering families

Medicare drug price negotiation legal challenge met with skepticism

hotspot

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

In same hospitals, Black patients receive fewer opioids than white patients

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

10 reasons why health care startups fail

Methadone doses haven’t kept up in the age of fentanyl

leisure time

focus

hotspot

knowledge